Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
News, developments and strategies related to eClinical, data management, data collection, ePRO, and more information technology used in the drug development chain. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
|
|
Synteract, a full service contract research organization (CRO), has implemented two Oracle® Argus 7.0 modules to its pharmacovigilance technology platform, Oracle Argus Safety and Oracle Argus Interchange. The information technology additions will enhance the safety data handling and electronic data efficiency, scalability and customization capabilities Synteract offers its biopharmaceutical clients conducting Phase I-IV clinical trials as well as those with post marketing pharmacovigilance needs. In conjunction, Synteract will now offer Oracle Argus Safety database hosting on a SaaS (software as a service) model for clients who would prefer specialists to handle implementation, validation and maintenance of their safety database and technology infrastructure. Synteract Director of IT Services Toby Odenheim says, “Our adoption of this software enables us to provide richer functionalities to our clients including more automation, customized workflow, and effective electronic exchange of data. This will increase study efficiencies, allow for more seamless exchange of information and improve access to study information, all of which helps our clients get to decision points faster. Pharmacovigilance is enhanced and case processing and reporting of adverse events will proceed in a more efficient, streamlined manner.”
|
|